Table 1. Consensus Expert Recommendations by KADA and agreement rate.

No.	Recommendations	Agreement (%)
1	EASI score is suitable for use in routine clinical practice for objective assessment of AD severity and monitoring.	97.3
2	Moderate AD is basically defined as an AD with 16≤EASI score<23.	97.3
3	Severe AD is basically defined as an AD with EASI score ≥23.	89.2
4	To assess AD severity once before treatment is proper enough to reflect patients' AD severity in moderate to severe AD patients.	100
5	AD with EASI score <16, but with lesions on the face, neck, hands, foot or genitalia is defined as moderate AD.	64.3
6	AD with 16≤EASI score<23, but with lesions on the face, neck, hands, foot or genitalia is defined as severe AD.	64.9
7	To use NRS is recommended for itching scale of AD.	100
8	AD with EASI score <16, but with daytime or night time NRS ≥7 is defined as moderate AD.	81.1
9	AD with 16≤EASI score<23, but with daytime or night time NRS ≥7 is defined as severe AD.	78.4
10	DLQI is recommended as a tool to assess the quality of life in AD patients.	100
11	AD with EASI score <16, but with DLQI >10 is defined as moderate AD.	73
12	AD with 16≤EASI score<23, but with DLQI >10 is defined as severe AD.	73
13	To check DLQI is indicated only in patients with EASI score <23 and itching NRS <7 before treatment.	85.3
14	AD with allergic or non-allergic comorbidities or complications (i.e., asthma, cataract, depression) that need systemic treatment should be considered as severe AD.	62.2

KADA: The Korean Atopic Dermatitis Association, EASI: eczema area and severity index, AD: atopic dermatitis, NRS: numerical rating scale, DLQI: dermatology life quality index.